CN115968279A - 一种药物制剂及其制备方法 - Google Patents

一种药物制剂及其制备方法 Download PDF

Info

Publication number
CN115968279A
CN115968279A CN202180037860.0A CN202180037860A CN115968279A CN 115968279 A CN115968279 A CN 115968279A CN 202180037860 A CN202180037860 A CN 202180037860A CN 115968279 A CN115968279 A CN 115968279A
Authority
CN
China
Prior art keywords
source
sodium
pharmaceutical formulation
pharmaceutical
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037860.0A
Other languages
English (en)
Inventor
莫毅
李洪湖
张玉权
唐玉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisike Pharmaceutical Co ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Liaoning Haisco Pharmaceutical Co Ltd
Haisco Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd, Liaoning Haisco Pharmaceutical Co Ltd, Haisco Pharmaceutical Group Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN115968279A publication Critical patent/CN115968279A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Abstract

一种包含GABAA受体增强剂和抑菌剂的药物制剂、其制备方法及其在制备用于诱导和维持动物或者人类的麻醉、促进动物或者人类的镇静催眠、治疗和/或预防焦虑、抑郁、失眠、恶心、呕吐、偏头痛、精神分裂、惊厥和癫痫药物中的应用，GABAA受体增强剂为式(I)或者其立体异构体、药学上可接受的盐或前药。其中R1、R2和n为说明书中定义的。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180037860.0A 2020-05-29 2021-05-28 一种药物制剂及其制备方法 Pending CN115968279A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010472446X 2020-05-29
CN202010472446 2020-05-29
PCT/CN2021/096890 WO2021239130A1 (zh) 2020-05-29 2021-05-28 一种药物制剂及其制备方法

Publications (1)

Publication Number Publication Date
CN115968279A true CN115968279A (zh) 2023-04-14

Family

ID=78722779

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037860.0A Pending CN115968279A (zh) 2020-05-29 2021-05-28 一种药物制剂及其制备方法

Country Status (5)

Country Link
US (1) US20230118143A1 (zh)
EP (1) EP4159197A4 (zh)
CN (1) CN115968279A (zh)
TW (1) TW202143951A (zh)
WO (1) WO2021239130A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579034A (zh) * 2014-09-04 2016-05-11 四川海思科制药有限公司 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途
CN106137963A (zh) * 2016-07-27 2016-11-23 武汉科福新药有限责任公司 抗心律失常药物脂肪乳注射液及其制备方法
CN109310676A (zh) * 2016-07-22 2019-02-05 四川海思科制药有限公司 一种苯酚衍生物和依托咪酯的药物组合物、药物制剂及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579034A (zh) * 2014-09-04 2016-05-11 四川海思科制药有限公司 一种gabaa受体增强剂用于制备镇静麻醉的药物中的用途
CN109310676A (zh) * 2016-07-22 2019-02-05 四川海思科制药有限公司 一种苯酚衍生物和依托咪酯的药物组合物、药物制剂及其用途
CN106137963A (zh) * 2016-07-27 2016-11-23 武汉科福新药有限责任公司 抗心律失常药物脂肪乳注射液及其制备方法

Also Published As

Publication number Publication date
TW202143951A (zh) 2021-12-01
EP4159197A1 (en) 2023-04-05
EP4159197A4 (en) 2023-11-22
US20230118143A1 (en) 2023-04-20
WO2021239130A1 (zh) 2021-12-02

Similar Documents

Publication Publication Date Title
AU2005208869B2 (en) Aqueous Pharmaceutical Compositions of 2,6-Diisopropylphenol (propofol) and Their Uses
CN103313729B (zh) 包括半氟化烷烃的o/w型乳剂
AU750040B2 (en) Propofol composition containing sulfite
US8759404B2 (en) Intravenous propofol emulsion compositions having preservative efficacy
JP4012328B2 (ja) エデテートを含有する水中油滴エマルジョン
EP1073467B1 (en) Co-solvent formulations comprising a vitamin d compound
JPH10510267A (ja) スフィンゴ脂質の投与に適したエマルジョン及びその使用
CN115968279A (zh) 一种药物制剂及其制备方法
US9132090B2 (en) Propofol based anesthetic with preservative
CN109431999B (zh) 一种纳米自微乳剂、兽药纳米自微乳剂及其制备方法与应用
EP1143962B1 (en) Parenteral solution of propofol (2,6-diisoprophylphenol) and 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol as a solvent
US20020173547A1 (en) Pharmaceuticals compositions
TW201832765A (zh) 膀胱內投藥用於治療膀胱痛之組合物
KR100358243B1 (ko) 프로포폴및에데테이트를함유하는수중유에멀션
KR100358244B1 (ko) 프로포폴 및 에데테이트를 함유하는 수중유 에멀션
CN111419797A (zh) 一种依托咪酯注射制剂及其制备方法
MXPA00007790A (en) Propofol composition containing sulfite

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231226

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: No. 136 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu, Sichuan Province, 611130

Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.

Applicant before: LIAONING HAISCO PHARMACEUTICAL Co.,Ltd.

Applicant before: HAISCO PHARMACEUTICAL Group Inc.